SAGE Therapeutics Inc. (SAGE)

181.67
NASDAQ : Health Technology
Prev Close 180.26
Day Low/High 179.01 / 182.25
52 Wk Low/High 79.88 / 193.56
Avg Volume 395.60K
Exchange NASDAQ
Shares Outstanding 51.15M
Market Cap 9.22B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on May 1, 2017, the Compensation...

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.

Sage Therapeutics Announces Initiation Of Phase 1 Development And First Dosing Of SAGE-718

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced it has initiated a Phase 1 single...

ILG, Wyndham Worldwide, Marriott Vacations Worldwide: 'Mad Money' Lightning Round

ILG, Wyndham Worldwide, Marriott Vacations Worldwide: 'Mad Money' Lightning Round

Jim Cramer is bullish on ILG, Wyndham Worldwide, Marriott Vacations Worldwide, plus Bank of America.

It's the Earnings, Not the Politics: Cramer's 'Mad Money' Recap (Tuesday 4/25/17)

It's the Earnings, Not the Politics: Cramer's 'Mad Money' Recap (Tuesday 4/25/17)

Jim Cramer maintains this rally is fueled by the strong performance of U.S. companies, but says it's worth assessing stock market valuations.

Sage Therapeutics To Report First Quarter 2017 Financial Results On Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Appoints Michael Cloonan As Chief Business Officer And Expands Executive Team

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the appointment of Michael Cloonan as...

Sage Therapeutics To Present At American Academy Of Neurology 2017 Annual Meeting

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced upcoming presentations for brexanolone...

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Takeaways and Observations; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Apple, Allergan and Western Digital.

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Biotechs Catching Their Breath: Cramer's 'Off The Charts'

Some recent high-flying biotechs may be preparing for their next surge.

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)

Political negatives keep popping up, forcing us to rethink the Trump trade, says Jim Cramer.

Sage Defies Adversity on Its Way Up

Sage Defies Adversity on Its Way Up

The stock keeps moving upwards, despite worries over pricing in biotech.

Chart of the Day: Sage Therapeutics

The stock defies the rhetoric and keeps going up.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on April 3, 2017, the Compensation...

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Biotech Premarket Movers: Sage Therapeutics, Depomed, NantKwest

Sage Therapeutics, Depomed and NantKwest were among the biotech stock movers in premarket trading on Friday.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

Biotech Stock Mailbag: Sage Therapeutics, Cellceutix, Alzheimer's Risk

TheStreet's Adam Feuerstein answers reader questions about biotech stocks.

Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on March 1, 2017, the Compensation...

Sage Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Sage Therapeutics, Inc. (NASDAQ: SAGE) today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2016.

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

Sage Therapeutics Leads Biotech Movers on False Takeout Rumors

In addition to Sage Therapeutics, also moving biotech Friday: Novavax, Cytokinetics and Acadia Pharmaceuticals.

Sage Therapeutics To Report Fourth Quarter And Full Year 2016 Financial Results On Thursday, February 23, 2017

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company will host a...

Sage Therapeutics Not In M&A Discussions: STATEMENT

Sage Therapeutics (NASDAQ: SAGE) - On February 16, 2017, Chief Executive Officer Jeff Jonas conducted an interview about SAGE-217 in major depressive disorder (MDD).

Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data

Sage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data

Depression represents a huge commercial market opportunity. It's also a disease in which drugs that show impressive results in early studies routinely flame out before reaching the finish line.

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Biotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics

Sage Therapeutics, Immunomedics and Myriad Genetics were among the premarket biotech stock movers on Monday.

Sage Therapeutics Advances SAGE-217 Into Placebo-Controlled Phase 2 Clinical Trial In Major Depressive Disorder

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced encouraging top-line results from...

Sage Therapeutics To Participate In Upcoming February Investor Conferences

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will participate in the...

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017

Sage Therapeutics To Present At J.P. Morgan Healthcare Conference On Tuesday, January 10, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the company is scheduled...

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Starbucks, Allergan, Amazon: Doug Kass' Views

Starbucks, Allergan, Amazon: Doug Kass' Views

Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'